Stockscreener 앱 받기
2.72
1.09%
-0.03
시간 외 거래:
2.72
전일 마감가:
$2.75
열려 있는:
$2.76
하루 거래량:
386.02K
Relative Volume:
0.55
시가총액:
$219.15M
수익:
$52.74M
순이익/손실:
$-6.60M
주가수익비율:
-32.19
EPS:
-0.0845
순현금흐름:
$-13.63M
1주 성능:
+1.12%
1개월 성능:
+13.33%
6개월 성능:
+25.93%
1년 성능:
+33.33%
1일 변동 폭
$2.70
$2.775
1주일 범위
$2.69
$2.8495
52주 변동 폭
$1.60
$3.19
Protalix BioTherapeutics Inc. Stock (PLX) Company Profile
명칭
Protalix BioTherapeutics Inc.
전화
972 4 988 9488
주소
2 Snunit Street, Science Park PO Box 455, Karmiel
Compare PLX vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PLX
Protalix BioTherapeutics Inc.
|
2.72 | 219.15M | 52.74M | -6.60M | -13.63M | -0.0845 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Protalix BioTherapeutics Inc. Stock (PLX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-06-08 | 재확인 | H.C. Wainwright | Buy |
| 2017-04-17 | 재확인 | Rodman & Renshaw | Buy |
| 2016-04-04 | 개시 | Rodman & Renshaw | Buy |
| 2015-04-23 | 업그레이드 | Jefferies | Hold → Buy |
| 2014-11-12 | 재확인 | R. F. Lafferty | Buy |
| 2014-01-24 | 개시 | R. F. Lafferty | Buy |
| 2012-05-02 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2012-05-02 | 재확인 | Oppenheimer | Outperform |
| 2012-04-30 | 다운그레이드 | Auriga | Buy → Hold |
| 2011-10-13 | 개시 | Morgan Joseph | Hold |
| 2011-03-17 | 다운그레이드 | WBB Securities | Strong Buy → Buy |
| 2010-11-09 | 재확인 | Oppenheimer | Outperform |
| 2010-10-14 | 재확인 | UBS | Buy |
| 2009-12-02 | 재확인 | Hapoalim | Outperform |
| 2009-09-22 | 개시 | Canaccord Adams | Buy |
| 2009-09-02 | 개시 | Hapoalim | Outperform |
| 2008-12-01 | 재확인 | Oppenheimer | Outperform |
| 2008-03-11 | 개시 | UBS | Buy |
| 2007-11-20 | 개시 | CIBC Wrld Mkts | Sector Outperform |
모두보기
Protalix BioTherapeutics Inc. 주식(PLX)의 최신 뉴스
Protalix at Morgan Stanley conference: rare-disease growth in focus By Investing.com - Investing.com Canada
Director at Protalix (NYSE: PLX) gets options expiring 2036 plus 8,500 RSUs - Stock Titan
PLX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $12 - GuruFocus
Protalix BioTherapeutics Grants 168,000 Derivative Securities to Executive Naos Yaron (AMEX: PLX) - Kalkine Media
Protalix BioTherapeutics (AMEX: PLX) Grants 25,500 Derivative Securities to Insider Forster Eliot - Kalkine Media
Protalix CFO is scheduled for two New York appearances this month - Stock Titan
Stock awards for Protalix (PLX) director vest quarterly to 2036 - Stock Titan
Protalix (NYSE: PLX) director receives new options and RSUs - Stock Titan
Protalix (NYSE: PLX) sets CEO equity to 3-year vesting, change-in-control terms - stocktitan.net
Yaron Naos awarded new equity at Protalix BioTherapeutics (PLX) - Stock Titan
Director at Protalix BioTherapeutics (PLX) gets new options and stock units - Stock Titan
Protalix (PLX) awards Amos Bar‑Shalev new 3‑year equity grant - Stock Titan
Board member at Protalix (PLX) gets new stock and option grant - Stock Titan
Zacks Research Issues Pessimistic Outlook for PLX Earnings - MarketBeat
Protalix (PLX) Q2 2026 Earnings Call Transcript - The Globe and Mail
Protalix (PLX) Q2 2026 Earnings Call Transcript - The Motley Fool
Protalix (PLX) Q2 2026 Filing Snapshot: EPS Clears the Reported Estimate in the Current Update; Share-Price Check - dars.gov.et
Protalix BioTherapeutics (NYSEAMERICAN:PLX) Advances Plant-Cell Protein Programs - Kalkine Media
Protalix BioTherapeutics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
PLX: Elfabrio Estimates Up - Yahoo Finance
Protalix BioTherapeutics Inc (PLX) (Q2 2026) Earnings Call Highlights: Net Income Surges to $3. ... - Yahoo! Finance Canada
Protalix BioTherapeutics Inc (PLX) (Q2 2026) Earnings Call Highl - GuruFocus
Earnings call transcript: Protalix posts stronger Q2 2026 revenue, shares slip premarket - Investing.com
Protalix BioTherapeutics Inc (PLX) Reports Q2 Earnings: $19.8M R - GuruFocus
Protalix BioTherapeutics, Inc. (PLX) Q2 FY2026 earnings call transcript - Yahoo Finance
Form 8K Protalix Biotherapeutics Inc For: 12 August By Investing.com - Investing.com South Africa
Protalix BioTherapeutics reports Q2 revenue gro... - Pluang
Protalix BioTherapeutics, Inc. 2026: Revenue $19.9M, EPS $0.05— 10-Q Summary - TradingView
Protalix BioTherapeutics (PLX) swings to $22.1M H1 profit on Elfabrio milestone - Stock Titan
Protalix Posts $19.9 Million Q2 Revenue and $3.8 Million Net Income - Quiver Quantitative
Protalix BioTherapeutics reports $53.6M YTD revenue, $22.1M net income in H1 2026 - TradingView
Protalix: Q2 Earnings Snapshot - 10TV
Protalix BioTherapeutics, Inc. Reaffirms Earnings Guidance for the Year 2026 - marketscreener.com
Protalix BioTherapeutics to Announce Second Quarter 2026 Financial Results and Business Update on August 12, 2026 - PR Newswire
Protalix BioTherapeutics (PLX) Slips 1% as Shares Hover Between Support and ResistanceFloat Adjusted Cap - dars.gov.et
Protalix BioTherapeutics, Inc. Share Price Live Today – AMEX:PLX Stock Price, Chart, News, History - Upstox
Earnings Preview: PLX to Report Financial Results Pre-market on August 12 - Moomoo
Protalix BioTherapeutics (PLX) Edges Higher Amid Consolidation Near SupportRetail Driven Moves - vinanet.vn
BlackRock (NYSE: BLK) discloses 5.02% ownership in Protalix BioTherapeutics (PLX) - Stock Titan
Protalix Biotherapeutics Inc (PLX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Price to earnings forward of Protalix Biotherapeutics, Inc. – MUN:PBDA - TradingView
Protalix Biotherapeutics Inc (PLX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Protalix Biotherapeutics Inc (PLX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
PLX|Protalix Biotherapeutics Inc|Price:2.640|Chg%:-0.090 - TradingKey
PLX|Protalix Biotherapeutics Inc|Price:2.440|Chg%:+0.070 - TradingKey
Protalix Biotherapeutics Inc (PLX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Protalix Biotherapeutics Inc (PLX) Institutional Confidence - TradingKey
Protalix Biotherapeutics Inc (PLX) Cash Flow - TradingKey
Protalix Biotherapeutics Inc (PLX) Earnings Date & Reports & Earnings News - TradingKey
Protalix BioTherapeutics Market Sentiment - Benzinga España
PLX|Protalix Biotherapeutics Inc|Price:2.220|Chg%:-0.145 - TradingKey
Protalix BioTherapeutics Inc. (PLX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.06%
2.55%
자본화:
|
볼륨(24시간):